Marketable Securities, Current of VERTEX PHARMACEUTICALS INC / MA from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of investment in marketable security, classified as current.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly Marketable Securities, Current in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Marketable Securities, Current for the quarter ending 31 Dec 2025 was $1,523,300,000, a 1.5% decline year-over-year.
Source SEC data
View on sec.gov
Marketable Securities, Current, Quarterly (USD)
Marketable Securities, Current, YoY Quarterly Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Marketable Securities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,523,300,000 -$23,000,000 -1.5% 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $1,347,400,000 +$62,100,000 +4.8% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $1,410,600,000 +$195,200,000 +16% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $1,526,500,000 +$513,200,000 +51% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $1,546,300,000 +$697,100,000 +82% 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $1,285,300,000 +$467,300,000 +57% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $1,215,400,000 +$130,200,000 +12% 30 Jun 2024 10-Q 02 Aug 2024 2024 Q2
Q1 2024 $1,013,300,000 -$110,900,000 -9.9% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $849,200,000 +$574,700,000 +209% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $818,000,000 +$218,800,000 +37% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $1,085,200,000 +$534,000,000 +97% 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 $1,124,200,000 +$486,200,000 +76% 31 Mar 2023 10-Q 02 May 2023 2023 Q1
Q4 2022 $274,500,000 -$455,400,000 -62% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $599,200,000 -$85,987,000 -13% 30 Sep 2022 10-Q 28 Oct 2022 2022 Q3
Q2 2022 $551,200,000 -$93,115,000 -14% 30 Jun 2022 10-Q 05 Aug 2022 2022 Q2
Q1 2022 $638,000,000 +$18,362,000 +3% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $729,900,000 +$59,200,000 +8.8% 31 Dec 2021 10-K 10 Feb 2023 2022 FY
Q3 2021 $685,187,000 -$107,784,000 -14% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 $644,315,000 +$24,878,000 +4% 30 Jun 2021 10-Q 30 Jul 2021 2021 Q2
Q1 2021 $619,638,000 +$22,654,000 +3.8% 31 Mar 2021 10-Q 30 Apr 2021 2021 Q1
Q4 2020 $670,700,000 -$28,272,000 -4% 31 Dec 2020 10-K 09 Feb 2022 2021 FY
Q3 2020 $792,971,000 +$194,581,000 +33% 30 Sep 2020 10-Q 30 Oct 2020 2020 Q3
Q2 2020 $619,437,000 -$37,101,000 -5.7% 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $596,984,000 +$12,834,000 +2.2% 31 Mar 2020 10-Q 01 May 2020 2020 Q1
Q4 2019 $698,972,000 +$180,864,000 +35% 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $598,390,000 +$20,807,000 +3.6% 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $656,538,000 +$34,142,000 +5.5% 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $584,150,000 +$103,026,000 +21% 31 Mar 2019 10-Q 01 May 2019 2019 Q1
Q4 2018 $518,108,000 +$94,854,000 +22% 31 Dec 2018 10-K 13 Feb 2020 2019 FY
Q3 2018 $577,583,000 30 Sep 2018 10-Q 25 Oct 2018 2018 Q3
Q2 2018 $622,396,000 30 Jun 2018 10-Q 26 Jul 2018 2018 Q2
Q1 2018 $481,124,000 31 Mar 2018 10-Q 27 Apr 2018 2018 Q1
Q4 2017 $423,254,000 31 Dec 2017 10-Q 25 Oct 2018 2018 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.